It is unfortunate that Richard Howard did not discover the benefits of integrative cancer therapy until the final year of his 10-year battle with cancer. His family credits integrative therapies with the gains that allowed him to remain with his family a while longer and the increased feelings of comfort and well-being he experienced during his final year.
Mr. Howard’s daughter Sara, who encouraged her father to try integrative therapies, told the Litchfield (Connecticut) County Times, “I was like, ‘Dad, why not just try it?’ … I researched it and saw all the beneficial things it could do. He did and it was like, ‘Wow!’ and opening up this door for him to a whole other side of medicine.”
An engineer, Mr. Howard was at first skeptical of integrative therapies but was quickly won over by the increased comfort, sense of well-being and mobility he experienced following his first few alternative cancer therapies. The pilot program Mr. Howard participated in was limited to the integration of several Eastern medicine techniques such as acupuncture and massage; but a fully-developed, comprehensive integrative immunotherapy program can offer cancer patients a plethora of beneficial alternative cancer treatment options designed to support and enhance each other.
The combination of two alternative cancer therapies that are still in experimental stages could have the power to transform cancer treatment. The breakthrough discovery was recently announced by Canadian researchers at the Children’s Hospital of Eastern Ontario Research Institute (CHEO).
The new cancer therapy combines two alternative cancer treatments pioneered at CHEO: a recently developed viral therapy and an apoptosis protein inhibitor developed nearly two decades ago. Separately, each treatment showed promise but had failed to have a significant impact on cancer remission results. However, when the two therapies were combined in the lab and tested on mice, the results were dramatic. Combination magnified the cancer-killing effect of both therapies, resulting in a 90% cure rate in laboratory mice.
“The discovery, in effect, takes a drug that knocks out the genes that make cancer cells ‘bullet proof’ – something like pulling the plug on those cells’ resistance to dying – and gives it an extra push by priming the body’s immune response.” as lead researcher Dr. John Bell explained to the Ottawa Citizen.
Like other immunotherapy cancer treatments, the Canadian discovery is non-toxic, safe for children, highly effective against cancer and has the potential to be applicable to many different forms of cancer. Clinical trials of the combination therapy are expected to be scheduled soon. If successful, the Canadians estimate it will take about a decade before the new treatment will be available to patients as a non-toxic alternative to traditional chemotherapy and radiation and the destructive toll they take on the body.
As a pioneer in the use of immunotherapy to treat cancer, Issels welcomes this promising new addition to the growing body of immunotherapy-based alternative cancer treatments that are changing the way cancer is treated.